Drug Database · Clinicians

Progesterone

Brands (16) Utrogestan, Exprogest, Progestedin…Show all

US brand (reference label): Prometrium; not a Philippine-registered brand.

Progesterone US FDA class
Progestogen [pregnen (4) derivative]; Progestin PH FDA category

Rx · Prescription drug23 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 1cf237ff-c4f8-4faa-a7aa-77599c856889, version date July 23, 2026 (Prometrium · Acertis Pharmaceuticals, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE PROMETRIUM ® (progesterone, USP) Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE PROMETRIUM ® (progesterone, USP) Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.

Contraindications

CONTRAINDICATIONS PROMETRIUM is contraindicated in women with any of the following conditions: 1. Hypersensitivity to its ingredients. PROMETRIUM Capsules contain peanut oil and is contraindicated in patients allergic to peanuts. 2. Abnormal genital bleeding of unknown etiology. 3. Known, suspected, or history of breast cancer. 4. Active deep vein thrombosis, pulmonary embolism or history of these conditions. 5. Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. 6. Known liver dysfunction or disease.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Prevention of Endometrial Hyperplasia PROMETRIUM Capsules should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to a postmenopausal woman with a uterus who is receiving daily conjugated estrogens tablets. Treatment of Secondary Amenorrhea PROMETRIUM Capsules may be given as a single daily dose of 400 mg at bedtime for 10 days. Some women may experience difficulty swallowing PROMETRIUM Capsules. For these women, PROMETRIUM Capsules should be taken with a glass of water while in the standing position.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Renal Insufficiency: The effect of renal impairment on the pharmacokinetics of PROMETRIUM Capsules has not been studied. F. Food–Drug Interaction Concomitant food ingestion increased the bioavailability of PROMETRIUM Capsules relative to a fasting state when administered to postmenopausal women at a dose of 200 mg. G.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

G. Pediatric Use PROMETRIUM Capsules are not indicated in children. Clinical studies have not been conducted in the pediatric population.

Dosing: Older adult

Geriatric use (US label) US FDA label

H. Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing PROMETRIUM Capsules to determine whether those over 65 years of age differ from younger subjects in their response to PROMETRIUM Capsules. The Women's Health Initiative Study In the Women's Health Initiative (WHI) estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age.

(See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders and Malignant neoplasms.) The Women's Health Initiative Memory Study In the Women's Health Initiative Memory Study (WHIMS) of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in the estrogen plus progestin ancillary study when compared to placebo. (See CLINICAL STUDIES.)

Dosage forms

Philippines

  • Soft gelatin oral capsule: 200 mg
  • Oral soft-gel capsule: 100 mg, 200 mg
  • Soft-gelatin capsule: 200 mg
  • Vaginal soft gel capsule: 100 mg, 200 mg
  • Vaginal soft-gel capsule: 200 mg
  • Soft gelatin capsule: 200 mg
  • Vaginal soft gelatin capsule: 200 mg
  • Vaginal tablet: 100 mg

Registered products in the Philippines

23 products registered with the Food and Drug Administration (FDA) Philippines list Progesterone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products23
Philippine FDA-registered products for Progesterone
Package insert
AltogestProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/PVDC Blister Pack x 10’s (Box of 30's and 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11028-03
Jan 6, 2027
CrinoneProgesterone
8% w/w Vaginal GelSingle use pre-filled white polyethylene applicator with a twist-off top wrapped up and sealed in a paper/aluminum/polyethylene foil over wrap (Box of 15 units)
Rx
Dendron Brands LimitedUnited Kingdom
Importer: Merck, Inc.Trader: Merck Serono Limited
DR-XY26966
May 16, 2031
EndometrinProgesterone
100mg Vaginal Tablet
Rx
QPharma AB
Metro Drug, Inc.
DR-XY41423
Dec 21, 2026
ExprogestProgesterone
100mg Vaginal Soft Gel CapsuleAluminum/ PVC-PE-PVDC Blister Pack (Box of 15's)
Rx
Laboratorios Leon Farma SASpain
Embil International Philippines, Inc.
DRP-12871
Oct 18, 2027
ExprogestProgesterone
200mg Vaginal Soft Gel CapsuleAluminum/ PVC-PE-PVDC Blister Pack (Box of 15's)
Rx
Laboratorios Leon Farma SASpain
Embil International Philippines, Inc.
DRP-12867
Oct 18, 2027
FemmitronProgesterone
200 mg Soft gelatin Oral capsuleAlu/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV Hormonals)India
Ambica International Corporation
DRP-11028
Jan 6, 2027
Femmitron-VProgesterone
200 mg Vaginal Soft Gelatin CapsuleAlu-PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV-Hormonals)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-19092
Oct 27, 2031
FroniquiestProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/ PVDC Blister Pack x 10’s (Box of 30's and 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Frontida Pharmaceutical IncorporatedImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11028-02
Jan 6, 2027
GestecureProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/PVDC Blister Pack x 10’s (Box of 30’s, 60’s and 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Medcare Asia Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-11027
Jan 6, 2032
GestprogyProgesterone
200 mg Soft Gelatin CapsuleAlu/PVDC Blister Pack x 10’s (Box of 30’s and 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11029
Jan 6, 2032
GestronProgesterone
200 mg Soft-Gelatin CapsuleAlu/PVC Blister pack x 10's (Box of 20's and 60's)
Rx
Celogen Pharma Pvt LtdIndia
Excelcare Inc.Importer: Pharmastar Int'l Trading Corp.
DR-XY44495
Apr 22, 2031
HeragestProgesterone
200 mg Soft-gelatin CapsuleClear PVC Blister Pack x 10's (Box of 100's)
Rx
Steril-Gene Life Sciences (P) LimitedIndia
UNILAB, Inc.
DR-XY44691
Jul 14, 2031
HormoPro 200Progesterone
200 mg Soft Gelatin Oral CapsuleAlu / PVDC Blister Pack x 10’s (Box of 30's and 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Vamsler Phils. Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11028-04
Jan 6, 2027
MiprogenProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/PVDC Blister Pack x 10's (Box of 100's)
Rx
Akums Drugs & Pharmaceuticals Ltd.(Plant IV- Hormonals)India
BSV Bioscience Phils, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11027-01
Apr 29, 2030
NeogestronProgesterone
200 mg Soft Gelatin Oral CapsuleAlu / PVDC Blister Pack x 10’s (Box of 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Excelcare, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11028-05
Jan 6, 2027
NoneProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/PVDC Blister Pack x 10's (Box of 30's, 60's and 100's)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV - Hormonal)India
Excelcare, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11027-03
Jan 6, 2027
ProgestedinProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/PVDC Blister Pack x 10’s (Box of 30’s, 60’s and 100’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Medchoice Women's Health (MCWH), Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-11027-02
Jan 6, 2032
ProgestedinProgesterone
200 mg Soft Gelatin Oral CapsuleAlu/PVDC Blister Pack x 10’s (Box of 30's)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant IV – Hormonals)India
Medchoice Women’s Health (MCWH), Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-11028-01
Jan 6, 2027
UtrogestanProgesterone
100 mg Oral Soft-gel CapsulePVC/PVDC/Aluminum Blister Pack x 15’s (Box of 30’s)
Rx
Olic (Thailand) LimitedThailand
Metro Drug, Inc.Trader: Besins Healthcare SA
DR-XY44909
Mar 2, 2031
UtrogestanProgesterone
100 mg Oral Soft-gel CapsulePVC/Aluminum Blister Pack x 15's (Box of 30's)
Rx
Cyndea Pharma S.L.Spain
A. Menarini Philippines, Inc.
DR-XY47547
Nov 19, 2026
UtrogestanProgesterone
200 mg Oral Soft-gel CapsulePVC/PVDC/Aluminum Blister Pack 1 x 7’s and 1 x 8’s Box of 15’s
Rx
Olic (Thailand) LimitedThailand
Metro Drug, Inc.Trader: Besins Healthcare SA
DR-XY44911
Mar 2, 2031
UtrogestanProgesterone
200 mg Vaginal Soft-gel CapsulePVC/PVDC/Aluminum Blister Pack by 1 x 7’s and 1 x 8’s (Box of 15’s); PVC/PVDC/Aluminum Blister Pack by 1 x 7’s and 1 x 8’s (Physician's Sample) (Box of 2's)
Rx
Olic (Thailand) LimitedThailand
Metro Drug, Inc.Trader: Besins Healthcare SA
DR-XY44910
Mar 2, 2031
UtrogestanProgesterone
200 mg Vaginal Soft-gel CapsuleBox of 15's containing:; 1 PVC/Alu Blister pack x 7's; 1 PVC/Alu Blister pack x 8's
Rx
Cyndea Pharma S.L.(Soria) Spain
Metro Drug, Inc.Trader: Besins Healthcare Benelux
DR-XY47548
Nov 19, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS 1. Cardiovascular disorders PROMETRIUM is contraindicated in females with active DVT, PE, arterial thromboembolic disease (e.g., stroke, MI) disease, or a history of these conditions (See CONTRAINDICATIONS). Immediately discontinue PROMETRIUM if a PE, DVT, stroke, or MI occurs or is suspected. If feasible, discontinue PROMETRIUM at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

The safety and efficacy of estrogen plus progestogen for the prevention of cardiovascular disorders has not been established. (See CLINICAL STUDIES) The Women’s Health Initiative (WHI) estrogen plus progestin trial reported increased risks of PE, DVT, stroke, and MI in postmenopausal women (50 to 79 years of age, average age 63.4 years) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.

Analyses were also conducted in women aged 50-59 years, a group of women more likely to present with new onset of moderate to severe VMS compared to women in other age groups in the trial. (See CLINICAL STUDIES.) Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin trial of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. a. Venous Thromboembolism In women aged 50 to 59 years, the WHI estrogen plus progestin trial reported a relative risk for PE of 2.05 (95% confidence interval [CI], 0.89, 4.71) for CE/MPA compared to placebo, with a risk difference of 6 per 10,000 women-years (WYs; 11 versus 5).

The relative risk for DVT was 3.01 (95% CI, 1.36, 6.66) in those receiving CE/MPA compared to placebo, with a risk difference of 10 per 10,000 WYs (15 versus 5). (See CLINICAL STUDIES). In the overall study population of women aged 50 to 79 years (average 63.4 years), the trial reported a relative risk for PE of 1.98 (95% CI, 1.36, 2.87) for CE/MPA compared to placebo, with a risk difference of 9 per 10,000 WYs (18 versus 9).

The relative risk for DVT was 1.87 (95% CI, 1.37, 2.54) for CE/MPA compared to placebo, with a risk difference of 12 per 10,000 WYs (25 versus 14). (See CLINICAL STUDIES). b. Stroke In women aged 50 to 59 years, the WHI estrogen plus progestin trial reported a relative risk for stroke of 1.51 (95% CI, 0.81, 2.82) for CE/MPA compared to placebo, with a risk difference of 5 per 10,000 WYs (15 versus 10).

(See CLINICAL STUDIES). In the overall study population of women aged 50 to 79 years (average 63.4 years), the WHI estrogen plus progestin trial reported relative risk for stroke of 1.37 (95% CI, 1.07, 1.76) for CE/MPA compared to placebo, with a risk difference of 9 per 10,000 WYs (33 versus 24). (See CLINICAL STUDIES). c.

Coronary Heart Disease In women 50 to 59 years of age,the WHI estrogen plus progestin trial reported a relative risk for coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) of 1.34 (95% CI, 0.82, 2.19) for CE/MPA compared placebo, with a risk difference of 5 per 10,000 WYs (23 versus 17). In the overall study population of women aged 50 to 79 years (average 63.4 years), the trial reported a relative risk of CHD of 1.18 (95% CI, 0.95, 1.45) for CE/MPA compared to placebo, with a risk difference of 6 per 10,000 WYs (41 versus 35).

(See CLINICAL STUDIES). In the Heart and Estrogen/Progestin Replacement Study (HERS) and open label extension (HERS II), postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years) received daily CE (0.625 mg) plus MPA or placebo. In Year 1, there were more CHD events in the CE plus MPA-treated group than placebo; however, rates of CHD events were comparable among both groups for the remainder of the duration of the studies (average total follow-up of 6.8 years). 2.

Malignant neoplasms a. Breast Cancer Prometrium is contraindicated in women with breast cancer, a history of breast cancer, or estrogen-dependent neoplasia. (See CONTRAINDICATIONS). Discontinue Prometrium if a hormone-sensitive malignancy is diagnosed. The use of estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.

Only daily oral CE 0.625 mg and MPA 2.5 mg were studied in the estrogen-alone trial of the WHI. Therefore, the relevance of the WHI findings regarding breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products.

In women 50-59 years of age, the WHI estrogen plus progestin trial reported a relative risk for invasive breast cancer of 1.21 (95% CI, 0.81, 1.80) for CE/MPA compared to placebo, with a risk difference of 6 per 10,000 WYs (33 versus 27). In this age group, among those who reported no prior use of hormone therapy, the relative risk was 1.06 (95% CI, 0.67, 1.67) for CE/MPA compared to placebo, with a risk difference of 2 per 10,000 WYs (33 versus 31).

In the overall study population of women aged 50-79 years (average 63.4 years), the WHI estrogen plus progestin trial reported a relative risk for invasive breast cancer of 1.24 (95% CI, 1.01, 1.53) for CE/MPA compared to placebo, with a risk difference of 9 per 10,000 WYs (43 versus 35). In the overall study population, among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.85, (95% CI 1.18, 2.90) for CE/MPA compared to placebo, with a risk difference of 21 per 10,000 WYs (46 versus 25).

Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, (95% CI 0.86, 1.39), with a risk difference of 4 per 10,000 WYs (40 versus 36). Invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group.

Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups. (See CLINICAL STUDIES.) Extension of the WHI trial also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy.

Consistent with the WHI trial, observational studies have also reported an increased risk of breast cancer with estrogen plus progestin therapy. A large meta-analysis including 24 prospective studies of postmenopausal women comparing current use of estrogen plus progestin products with use duration of 5 to 14 years (average of 9 years) versus never use reported a relative risk for breast cancer of 2.08 (95% CI, 2.02 to 2.15).

These studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration. Regarding breast cancer mortality, the WHI estrogen plus progestin trial did not show a statistically significant difference between CE/MPA and placebo.

The trial reported a relative risk of 1.35 (95% CI, 0.94 to 1.95) for CE/MPA compared to placebo, with a risk difference of 1 per 10,000 WYs (5 versus 4) after a median of 19 years of cumulative follow-up. b. Ovarian Cancer In the overall WHI study population of women aged 50 to 79 years (average 63.4 years), the estrogen plus progestin trial reported a relative risk for ovarian cancer of 1.41 (95% CI, 0.75 to 2.66) for CE/MPA versus placebo after an average follow-up of 5.6 years.

The risk difference was 1 per 10,000 WYs (5 versus 4). Comparing CE/MPA to placebo, women 50 to 59 years of age had a relative risk for ovarian cancer of 0.30 (95% CI 0.06, 1.47) and the risk difference was -3 per 10,000 WYs (1 versus 4). A large meta-analysis including 17 prospective studies of postmenopausal women compared current use of estrogen plus progestin products versus never use and reported a relative risk for ovarian cancer of 1.37 (95% CI, 1.26 to 1.48).

The duration of hormone therapy use that was associated with an increased risk of ovarian cancer is unknown. 3. Vision abnormalities Retinal vascular thrombosis has been reported in patients receiving estrogen. Discontinue estrogen plus progestin therapy pending examination if there is sudden partial or complete loss of vision, or if there is a sudden onset of proptosis, diplopia or migraine.

If examination reveals papilledema or retinal vascular lesions, estrogen plus progestin therapy should be permanently discontinued.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS See WARNINGS and PRECAUTIONS. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of PROMETRIUM Capsules on the endometrium was studied in a total of 875 postmenopausal women.

Table 7 lists adverse reactions greater than or equal to 2 percent of women who received cyclic PROMETRIUM Capsules 200 mg daily (12 days per calendar month cycle) with 0.625 mg conjugated estrogens or placebo. TABLE 7. Adverse Reactions (≥ 2%) Reported in an 875 Patient Placebo-Controlled Trial in Postmenopausal Women Over a 3-Year Period [Percentage (%) of Patients Reporting] PROMETRIUM Capsules 200 mg with Conjugated Estrogens 0.625 mg Placebo (n=178) (n=174) Headache 31 27 Breast Tenderness 27 6 Joint Pain 20 29 Depression 19 12 Dizziness 15 9 Abdominal Bloating 12 5 Hot Flashes 11 35 Urinary Problems 11 9 Abdominal Pain 10 10 Vaginal Discharge 10 3 Nausea / Vomiting 8 7 Worry 8 4 Chest Pain 7 5 Diarrhea 7 4 Night Sweats 7 17 Breast Pain 6 2 Swelling of Hands and Feet 6 9 Vaginal Dryness 6 10 Constipation 3 2 Breast Carcinoma 2 <1 Breast Excisional Biopsy 2 <1 Cholecystectomy 2 <1 Effects on Secondary Amenorrhea In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of PROMETRIUM ® (progesterone, USP) Capsules on secondary amenorrhea was studied in 49 estrogen-primed postmenopausal women.

Table 8 lists adverse reactions greater than or equal to 5 percent of women who received PROMETRIUM Capsules or placebo. TABLE 8. Adverse Reactions (≥ 5%) Reported in Patients Using 400 mg/day in a Placebo-Controlled Trial in Estrogen-Primed Postmenopausal Women Adverse Experience PROMETRIUM Capsules 400 mg Placebo n=25 n=24 Percentage (%) of Patients Fatigue 8 4 Headache 16 8 Dizziness 24 4 Abdominal Distention (Bloating) 8 8 Abdominal Pain (Cramping) 20 13 Diarrhea 8 4 Nausea 8 0 Back Pain 8 8 Musculoskeletal Pain 12 4 Irritability 8 4 Breast Pain 16 8 Infection Viral 12 0 Coughing 8 0 In a multicenter, parallel-group, open label postmarketing dosing study consisting of three consecutive 28-day treatment cycles, 220 premenopausal women with secondary amenorrhea were randomized to receive daily conjugated estrogens therapy (0.625 mg conjugated estrogens) and PROMETRIUM Capsules, 300 mg per day (n=113) or PROMETRIUM Capsules, 400 mg per /day (n=107) for 10 days of each treatment cycle.

Overall, the most frequently reported treatment-emergent adverse reactions, reported in greater than or equal to 5 percent of subjects, were nausea, fatigue, vaginal mycosis, nasopharyngitis, upper respiratory tract infection, headache, dizziness, breast tenderness, abdominal distension, acne, dysmenorrhea, mood swing, and urinary tract infection. Postmarketing Experience: The following additional adverse reactions have been reported with PROMETRIUM Capsules.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure. Genitourinary System: endometrial carcinoma, hypospadia, intra-uterine death, menorrhagia, menstrual disorder, metrorrhagia, ovarian cyst, spontaneous abortion.

Cardiovascular: circulatory collapse, congenital heart disease (including ventricular septal defect and patent ductus arteriosus), hypertension, hypotension, tachycardia. Gastrointestinal: acute pancreatitis, cholestasis, cholestatic hepatitis, dysphagia, hepatic failure, hepatic necrosis, hepatitis, increased liver function tests (including alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased), jaundice, swollen tongue.

Skin: alopecia, pruritus, urticaria. Eyes: blurred vision, diplopia, visual disturbance. Central Nervous System: aggression, convulsion, depersonalization, depressed consciousness, disorientation, dysarthria, loss of consciousness, paresthesia, sedation, stupor, syncope (with and without hypotension), transient ischemic attack, suicidal ideation.

During initial therapy, a few women have experienced a constellation of many or all of the following symptoms: extreme dizziness and/or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion, disorientation, feeling drunk, and shortness of breath. Miscellaneous: abnormal gait, anaphylactic reaction, arthralgia, blood glucose increased, choking, cleft lip, cleft palate, difficulty walking, dyspnea, face edema, feeling abnormal, feeling drunk, hypersensitivity, asthma, muscle cramp, throat tightness, tinnitus, vertigo, weight decreased, weight increased.

Adverse reaction frequency tables (US label) US FDA label
TABLE 7. Adverse Reactions (≥ 2%) Reported in an 875 Patient Placebo-Controlled Trial in Postmenopausal Women Over a 3-Year Period [Percentage (%) of Patients Reporting]
PROMETRIUM Capsules 200 mg with Conjugated Estrogens 0.625 mgPlacebo
(n=178)(n=174)
Headache3127
Breast Tenderness276
Joint Pain2029
Depression1912
Dizziness159
Abdominal Bloating125
Hot Flashes1135
Urinary Problems119
Abdominal Pain1010
Vaginal Discharge103
Nausea / Vomiting87
Worry84
Chest Pain75
Diarrhea74
Night Sweats717
Breast Pain62
Swelling of Hands and Feet69
Vaginal Dryness610
Constipation32
Breast Carcinoma2<1
Breast Excisional Biopsy2<1
Cholecystectomy2<1
TABLE 8. Adverse Reactions (≥ 5%) Reported in Patients Using 400 mg/day in a Placebo-Controlled Trial in Estrogen-Primed Postmenopausal Women
Adverse ExperiencePROMETRIUM Capsules 400 mgPlacebo
n=25n=24
Percentage (%) of Patients
Fatigue 84
Headache 168
Dizziness 244
Abdominal Distention (Bloating) 88
Abdominal Pain (Cramping) 2013
Diarrhea 84
Nausea 80
Back Pain 88
Musculoskeletal Pain 124
Irritability 84
Breast Pain 168
Infection Viral 120
Coughing 80

Pregnancy considerations

Pregnancy (US label) US FDA label

E. Pregnancy PROMETRIUM Capsules should not be used during pregnancy. Pregnancy Category B: Reproductive studies have been performed in mice at doses up to 9 times the human oral dose, in rats at doses up to 44 times the human oral dose, in rabbits at a dose of 10 mcg/day delivered locally within the uterus by an implanted device, in guinea pigs at doses of approximately one-half the human oral dose and in rhesus monkeys at doses approximately the human dose, all based on body surface area, and have revealed little or no evidence of impaired fertility or harm to the fetus due to progesterone.

Breastfeeding considerations

Lactation (US label) US FDA label

F. Nursing Women Detectable amounts of progestin have been identified in the milk of nursing women receiving progestins. Caution should be exercised when PROMETRIUM Capsules are administered to a nursing woman.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Progesterone metabolites which are excreted in the bile may be deconjugated and may be further metabolized in the intestine via reduction, dehydroxylation, and epimerization.

Excretion The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the bile and urine.

Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces.

The half-life of the conjugated estrogens was similar with coadministration of PROMETRIUM Capsules.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics A. Absorption After oral administration of progesterone as a micronized soft-gelatin capsule formulation, maximum serum concentrations were attained within 3 hours. The absolute bioavailability of micronized progesterone is not known. Table 1 summarizes the mean pharmacokinetic parameters in postmenopausal women after five oral daily doses of PROMETRIUM Capsules 100 mg as a micronized soft-gelatin capsule formulation.

TABLE 1. Pharmacokinetic Parameters of PROMETRIUM Capsules Parameter PROMETRIUM Capsules Daily Dose 100 mg 200 mg 300 mg C max (ng/mL) 17.3 ± 21.9 Mean ± S.D. 38.1 ± 37.8 60.6 ± 72.5 T max (hr) 1.5 ± 0.8 2.3 ± 1.4 1.7 ± 0.6 AUC (0-10) (ng × hr/mL) 43.3 ± 30.8 101.2 ± 66.0 175.7 ± 170.3 Serum progesterone concentrations appeared linear and dose proportional following multiple dose administration of PROMETRIUM ® (progesterone, USP) Capsules 100 mg over the dose range 100 mg per day to 300 mg per day in postmenopausal women.

Although doses greater than 300 mg per day were not studied in females, serum concentrations from a study in male volunteers appeared linear and dose proportional between 100 mg per day and 400 mg per day. The pharmacokinetic parameters in male volunteers were generally consistent with those seen in postmenopausal women.

B. Distribution Progesterone is approximately 96 percent to 99 percent bound to serum proteins, primarily to serum albumin (50 to 54 percent) and transcortin (43 to 48 percent). C. Metabolism Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites.

Progesterone metabolites which are excreted in the bile may be deconjugated and may be further metabolized in the intestine via reduction, dehydroxylation, and epimerization. D. Excretion The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the bile and urine. Progesterone metabolites are eliminated mainly by the kidneys.

Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. E. Special Populations The pharmacokinetics of PROMETRIUM Capsules have not been assessed in low body weight or obese patients. Hepatic Insufficiency: The effect of hepatic impairment on the pharmacokinetics of PROMETRIUM Capsules has not been studied.

Renal Insufficiency: The effect of renal impairment on the pharmacokinetics of PROMETRIUM Capsules has not been studied. F. Food–Drug Interaction Concomitant food ingestion increased the bioavailability of PROMETRIUM Capsules relative to a fasting state when administered to postmenopausal women at a dose of 200 mg. G. Drug Interactions The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC 50 < 0.1 μM).

Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. The clinical relevance of the in vitro findings is unknown. Coadministration of conjugated estrogens and PROMETRIUM Capsules to 29 postmenopausal women over a 12-day period resulted in an increase in total estrone concentrations (C max 3.68 ng/mL to 4.93 ng/mL) and total equilin concentrations (C max 2.27 ng/mL to 3.22 ng/mL) and a decrease in circulating 17β estradiol concentrations (C max 0.037 ng/mL to 0.030 ng/mL).

The half-life of the conjugated estrogens was similar with coadministration of PROMETRIUM Capsules. Table 2 summarizes the pharmacokinetic parameters. TABLE 2. Mean (± S.D.) Pharmacokinetic Parameters for Estradiol, Estrone, and Equilin Following Coadministration of Conjugated Estrogens 0.625 mg and PROMETRIUM Capsules 200 mg for 12 Days to Postmenopausal Women Conjugated Estrogens Conjugated Estrogens plus PROMETRIUM Capsules Drug C max (ng/mL) T max (hr) AUC (0-24h) (ng × h/mL) C max (ng/mL) T max (hr) AUC (0-24h) (ng × h/mL) Estradiol 0.037 ± 0.048 12.7 ± 9.1 0.676 ± 0.737 0.030 ± 0.032 17.32 ± 1.21 0.561 ± 0.572 Estrone Total Total estrogens is the sum of conjugated and unconjugated estrogen. 3.68 ± 1.55 10.6 ± 6.8 61.3 ± 26.36 4.93 ± 2.07 7.5 ± 3.8 85.9 ± 41.2 Equilin Total 2.27 ± 0.95 6.0 ± 4.0 28.8 ± 13.0 3.22 ± 1.13 5.3 ± 2.6 38.1 ± 20.2

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Prometrium · Acertis Pharmaceuticals, LLC [US FDA-approved label, version 4, July 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .